Dr. David Waddell’s NIH-funded research project will help contribute to knowledge about skeletal muscle atrophy associated with neuromuscular disorders, neurodegenerative diseases and aging.

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motoneurons and skeletal muscle atrophy. In its most severe form, it leads to death before the age ...

In addition, MEPB ameliorated neuronal loss, neurogenic atrophy and testicular atrophy, validating AF2 modulation as a potent androgen-sparing strategy for SBMA therapy.

Dr. David Waddell's NIH-funded research project will help contribute to knowledge about skeletal muscle atrophy associated with neuromuscular disorders, neurodegenerative diseases and aging.

About Multiple System Atrophy (MSA) and Symptomatic Neurogenic Orthostatic Hypotension (nOH) MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the ...

--Theravance Biopharma, Inc. today announced that the US Food and Drug Administration has granted Orphan Drug Designation status to ampreloxetine for the treatment of symptomatic neurogenic ...

Researchers are detailing multiple cases of distal spinal muscular atrophy (dSMA) caused by vaccinia-related kinase 1 (VRK1) variants.. Based on their findings, coming from 4 patients with adult ...

DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced new analyses of the initial Phase 3 program of ampreloxetine ...

Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple ...

Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple ...

DUBLIN, April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ...